GlassScriptPhysician profile
Karen W Garrett
NPI 1912071796
$7,107.88
in general payments reported to CMS, 2019-2025
31 companies · $867 in 2025
The $867 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,083 · 2022: $2,872 · 2023: $1,158 · 2024: $1,128 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,062 · Education: $74.44 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,062.28 |
| Education | $74.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,230.93 | 2021-2025 | |
| Novo Nordisk INC | $394.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $299.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $265.97 | 2021-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $199.20 | 2021-2024 | Veozah, Myrbetriq |
| Allergan, INC. | $195.17 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $158.10 | 2021-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $155.97 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.66 | 2022-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $140.42 | 2023-2025 | Rexulti |
| Pfizer INC. | $93.91 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $82.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $82.36 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $81.82 | 2021-2024 | Nexletol |
| Abbott Laboratories | $61.94 | 2024-2025 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.38 | 2022-2023 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $53.52 | 2021 | |
| Boston Scientific Corporation | $51.52 | 2023-2024 | Watchman Flx, Varithena Administration Pack |
| Biohaven Pharmaceuticals, INC. | $46.60 | 2021 | |
| Philips North America LLC | $43.15 | 2024 | (Cm9) Amb Mon & Diag Und |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.35 | 2023 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $39.86 | 2021-2022 | |
| Inspire Medical Systems, INC. | $38.32 | 2023 | Inspire |
| Lexicon Pharmaceuticals, INC. | $23.35 | 2023 | Inpefa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.90 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $19.07 | 2023 | Gemtesa |
| Angiodynamics, INC. | $15.87 | 2023 | Auryon Laser System 100-120 Vac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.73 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.26 | 2023 | Quviviq |
| Medtronic, INC. | $14.07 | 2025 | Closurefast |
| Bayer Healthcare Pharmaceuticals INC. | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.